Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.47 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22468165 | 0.88 | HRH3 (0.47) | HRH3HMOX1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22468169 | 0.84 | HRH3 (0.49) | HRH3NPC1RAB9ALMNATP53 | |
| SCHEMBL16566705 | 0.83 | HRH3 (0.56) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL14935322 | 0.83 | HRH3 (0.56) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL14935135 | 0.81 | HRH3 (0.54) | HRH3NPC1RAB9AFAAHLMNA | |
| SCHEMBL3036065 | 0.79 | QPCT (0.55) | HRH3HMOX1QPCTFAAHLMNA | |
| SCHEMBL3032094 | 0.77 | QPCT (0.64) | HRH3HMOX1QPCTFAAHLMNA | |
| SCHEMBL16566810 | 0.75 | HRH3 (0.58) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL3030694 | 0.74 | QPCT (0.57) | HRH3QPCTFAAHLMNA | |
| SCHEMBL16567294 | 0.73 | HRH3 (0.60) | HRH3NPC1RAB9AFAAHTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | Celltaxsis, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2020-10-01 | — | — | US | disclosed |
| EP-1976828-B1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | HRH3 21/4885HMOX1 2757/4885CYP19A1 612/4885 |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | HRH3 21/4885HMOX1 2757/4885CYP19A1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.